Humana (HUM)
(Delayed Data from NYSE)
$355.19 USD
+8.04 (2.32%)
Updated May 16, 2024 03:59 PM ET
After-Market: $355.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$355.19 USD
+8.04 (2.32%)
Updated May 16, 2024 03:59 PM ET
After-Market: $355.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Zacks News
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $472.50 in the latest trading session, marking a +0.73% move from the prior day.
The Zacks Analyst Blog Highlights Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group
by Zacks Equity Research
Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group are part of the Zacks top Analyst Blog.
Humana (HUM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $471.98, marking a +1.49% move from the previous day.
Top Analyst Reports for Humana, Cintas & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Humana Inc. (HUM), Cintas Corporation (CTAS) and Biogen Inc. (BIIB).
Humana (HUM) Down 5.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Hold Humana (HUM) in Portfolio
by Zacks Equity Research
Humana (HUM) remains well-poised for growth on the back of an expanding Medicare Advantage membership, upgraded health plan offering suite and solid cash reserves.
Humana (HUM) to Provide In-home Care With Primary Care Anywhere
by Zacks Equity Research
Humana (HUM) enhances its CenterWell brand with the launch of Primary Care Anywhere.
Why Humana (HUM) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 HMO Stocks to Watch Amid Growing Premiums & Membership
by Debasmita Chatterjee
Expanding customer base, contract wins and a rapidly growing aging U.S. population will likely drive the performances of the Zacks Medical-HMO industry players. UNH, CI, HUM, CNC and MOH are poised to benefit from favorable industry trends.
Humana (HUM) to Bring Enhanced Kidney Care to MA Members
by Zacks Equity Research
Humana (HUM) makes Interwell's extensive resources available to its MA members grappling with CKD and ESKD, and hence bring about better health outcomes for them.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Encompass Health's (EHC) Q2 Earnings Beat, '23 EPS View Raised
by Zacks Equity Research
Encompass Health's (EHC) Q2 results reflect a growing patient base and improved net patient revenue per discharge. Management anticipates 2023 adjusted EPS within $3.31-$3.53, up from the earlier view of $2.94-$3.23.
Company News for Aug 3, 2023
by Zacks Equity Research
Companies in The News Are: VRTX, DVN, AFL, HUM
Humana (HUM) Q2 Earnings Beat on Strong Individual MA Unit
by Zacks Equity Research
Humana's (HUM) Q2 results gain from strong pharmacy revenues and revenue growth within the Insurance segment, partly offset by higher benefits expenses.
Private Sector Jobs Come in Higher Than Expected
by Zacks Equity Research
Private Sector Jobs Come in Higher Than Expected.
ADP Jobs +324K Still Higher than Expected; CVS, KHC, HUM Report
by Mark Vickery
ADP Chief Economist Nela Richardson said, "The economy is doing better than expected... we continue to see a slowdown in pay growth without broad-based job loss."
Humana (HUM) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Humana (HUM) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Humana (HUM) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 0.68% and 0.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Humana (HUM) Q2 Earnings Beat on Strong Pharmacy Business?
by Zacks Equity Research
Humana's (HUM) second-quarter results are likely to reflect rising premiums and investment income.
5 Low-Leverage Stocks to Buy Following the Fed Rate Hike
by Aparajita Dutta
The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You may buy HUM, TEX, ARI, ATO and TNK.
Centene (CNC) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 2.44% and 3.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Molina (MOH) Q2 Earnings Beat on High Premiums, '23 View Raised
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter results are aided by increased membership, and Medicaid and Medicare strength.
Humana (HUM) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Humana (HUM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $454.34, marking a +0.2% move from the previous day.
Here's What to Expect From Acadia Healthcare's (ACHC) Q2 Earnings
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q2 results are likely to reflect increased patient volumes across its U.S. operations, partly offset by a higher expense base.